Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Quick Listen: Scrip’s Five Must-Know Things

Executive Summary

This time we touch on Pfizer’s R&D plans, real-world evidence for coronavirus vaccines, a new approval in lung cancer, challenges for Galapagos, and Takeda's pipeline story.

You may also be interested in...



Takeda’s Andy Plump Tells The Japanese Pharma’s New Story

As Takeda pays down debt associated with the acquisition of Shire and advances R&D programs toward global filings, the company is selling its growth plan to investors – but are they buying?

Real-World Data Confirm Pfizer and AZ COVID-19 Vaccine Efficacy – And Bolster UK Dosing Policy

Observational studies from the National Health Service show encouraging signs for the UK’s vaccination program.

Pfizer Embraces Biotech-Like Speed To Advance BCMA Bispecific

Chris Boshoff, Pfizer Oncology chief development officer, said lessons from the rapid pace of the company’s COVID-19 vaccine program are being applied to elranatamab and other cancer therapies.

Related Content

UsernamePublicRestriction

Register

SC143911

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel